MX2016000611A - Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. - Google Patents

Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.

Info

Publication number
MX2016000611A
MX2016000611A MX2016000611A MX2016000611A MX2016000611A MX 2016000611 A MX2016000611 A MX 2016000611A MX 2016000611 A MX2016000611 A MX 2016000611A MX 2016000611 A MX2016000611 A MX 2016000611A MX 2016000611 A MX2016000611 A MX 2016000611A
Authority
MX
Mexico
Prior art keywords
fusokines
strongly reduced
receptor binding
binding affinities
reduced receptor
Prior art date
Application number
MX2016000611A
Other languages
English (en)
Inventor
Tavernier Jan
Bultinck Jennyfer
Sarah Gerlo
Uzé Gilles
Paul Franciane
Bordat Yann
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of MX2016000611A publication Critical patent/MX2016000611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una proteína de fusión que comprende al menos dos citosinas, de las cuales al menos es una citosina modificada con una afinidad de unión considerablemente menor a su receptor o a uno de sus receptores. Preferentemente, ambas citosinas se conectan mediante un enlazador, preferentemente un enlazador GGS. La invención se relaciona además de dicha proteína de fusión para su uso en el tratamiento de enfermedades.
MX2016000611A 2013-07-18 2014-07-03 Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. MX2016000611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306034 2013-07-18
PCT/EP2014/064227 WO2015007536A2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Publications (1)

Publication Number Publication Date
MX2016000611A true MX2016000611A (es) 2016-09-29

Family

ID=48906191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000611A MX2016000611A (es) 2013-07-18 2014-07-03 Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.

Country Status (15)

Country Link
US (3) US10640542B2 (es)
EP (2) EP3022305B1 (es)
JP (2) JP6580037B2 (es)
KR (1) KR102322510B1 (es)
CN (2) CN105705641B (es)
AU (2) AU2014292371B2 (es)
BR (1) BR112016001036B1 (es)
CA (1) CA2917937C (es)
DK (1) DK3299466T3 (es)
ES (2) ES2657060T3 (es)
HK (1) HK1252831A1 (es)
IL (1) IL243451B (es)
MX (1) MX2016000611A (es)
SG (2) SG10201808738WA (es)
WO (1) WO2015007536A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3411398B1 (en) 2016-02-05 2024-04-03 Orionis Biosciences BV Targeted therapeutic agents and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
CN109689087B (zh) 2016-05-13 2023-04-04 奥里尼斯生物科学私人有限公司 靶向性突变干扰素-β及其用途
WO2017194782A2 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
JP7476467B2 (ja) 2017-02-06 2024-05-01 オリオンズ バイオサイエンス ビーブイ 標的化キメラタンパク質及びその使用
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7347899B2 (ja) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
WO2019032663A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. PD-1 AND PD-L1 BINDING AGENTS
KR102659140B1 (ko) 2017-08-09 2024-04-19 오리오니스 바이오사이언시스 인코포레이티드 Clec9a 결합제 및 그의 용도
KR20200081438A (ko) 2017-10-31 2020-07-07 웨스턴 온콜리틱스 리미티드 전신 전달을 위한 플랫폼 종양용해 벡터
EP3749295A4 (en) 2018-02-05 2022-04-27 Orionis Biosciences, Inc. FIBROBLAST BINDING AGENTS AND USES THEREOF
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
EP3946410A4 (en) 2019-03-28 2023-06-28 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
WO2022011005A1 (en) * 2020-07-07 2022-01-13 Orionis Biosciences, Inc. Immunostimulatory adjuvants
BR112023022681A2 (pt) * 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
US20240166706A1 (en) * 2022-11-21 2024-05-23 Wisconsin Alumni Research Foundation Synthetic il6-il1beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE103932T1 (de) * 1989-08-22 1994-04-15 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
RU2263118C2 (ru) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
WO2008014612A1 (en) 2006-08-02 2008-02-07 Mcgill University Fusion proteins and methods for modulation of immune response
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
EP2200634B1 (en) 2007-09-21 2015-02-11 The Regents of The University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
AR077879A1 (es) 2009-08-17 2011-09-28 Roche Glycart Ag Inmunoconjugados dirigidos
WO2011029870A1 (en) 2009-09-10 2011-03-17 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
JP5907877B2 (ja) * 2009-11-02 2016-04-26 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ サイトカイン送達のためのヴォールト（ｖａｕｌｔ）複合体
WO2011079077A1 (en) * 2009-12-23 2011-06-30 Gradalis, Inc. Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
AU2011243965A1 (en) * 2010-04-22 2012-12-06 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center High affinity leptins and leptin antagonists
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
BR112014017876B1 (pt) * 2012-01-20 2023-04-11 Centre Hospitalier Regional Universitaire De Montpellier Constructo direcionador compreendendo interferon alfa 2 humano mutante e composição farmacêutica contendo o mesmo
WO2013134138A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
CA2965414C (en) * 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants

Also Published As

Publication number Publication date
CN105705641B (zh) 2021-07-13
CN110835376B (zh) 2023-08-04
KR20160108291A (ko) 2016-09-19
US11358997B2 (en) 2022-06-14
EP3022305A2 (en) 2016-05-25
EP3022305B1 (en) 2017-11-01
US20180155404A1 (en) 2018-06-07
CN110835376A (zh) 2020-02-25
SG11201600163VA (en) 2016-02-26
WO2015007536A2 (en) 2015-01-22
BR112016001036B1 (pt) 2023-02-23
US20190010199A1 (en) 2019-01-10
AU2014292371A1 (en) 2016-02-04
JP2016525516A (ja) 2016-08-25
DK3299466T3 (da) 2019-11-18
ES2657060T3 (es) 2018-03-01
JP2020002155A (ja) 2020-01-09
HK1252831A1 (zh) 2019-06-06
ES2757501T3 (es) 2020-04-29
CA2917937C (en) 2022-11-01
IL243451B (en) 2019-10-31
EP3299466A1 (en) 2018-03-28
AU2018203868A1 (en) 2018-06-21
SG10201808738WA (en) 2018-11-29
JP6853317B2 (ja) 2021-03-31
US20230054612A1 (en) 2023-02-23
WO2015007536A3 (en) 2015-03-19
CA2917937A1 (en) 2015-01-22
CN105705641A (zh) 2016-06-22
EP3299466B1 (en) 2019-09-11
IL243451A0 (en) 2016-03-31
KR102322510B1 (ko) 2021-11-08
JP6580037B2 (ja) 2019-09-25
BR112016001036A2 (pt) 2017-10-24
AU2014292371B2 (en) 2018-03-29
US10640542B2 (en) 2020-05-05
AU2018203868B2 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2016000611A (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
EA201791093A1 (ru) Антитела к cd47, способы и применение
MX2016010953A (es) Proteinas de fc multimericas.
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
PH12016500123A1 (en) Therapeutic fusion protein
MX2013013832A (es) Proteínas de unión receptoras fc.
PL3200822T3 (pl) Cząsteczki wiążące, zwłaszcza przeciwciała, które wiążą się z l1cam (cd171)
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12016500753B1 (en) Antibodies specific to fcrn
EP3551228A4 (en) ANTIBODIES FOR HUMAN ALPHA SYNUCLEIN
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
EP3297662A4 (en) ANTIBODY BINDING TO AXL PROTEINS
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
EP3339320A4 (en) CHIMERIC ANTIBODY RECEPTOR WITH AN ANTI-COTININ ANTIBODY BELARED AND USE THEREOF
DK3020732T3 (da) Immunoglobulin-Fc-konjugat, som bevarer immunoglobulin-Fc-fragmentets bindingsaffinitet til FcRn
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
MX2017007747A (es) Anticuerpos para il-17c.
MY180477A (en) New polypeptides
IL273202A (en) Human thrombin receptor binding proteins, PAR4
EP3297663A4 (en) Antibodies that bind to axl proteins
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SULZER MANAGEMENT AG

FG Grant or registration